Laura Huppert, MD, highlights patient-reported outcomes from the phase 3 ASCENT-04 trial which compared first-line treatment ...

Astellas Pharma announces positive topline results from phase 3 EV-304 clinical trial of Padcev plus Keytruda: Tokyo Friday, December 19, 2025, 10:00 Hrs [IST] Astellas Pharma Inc ...

Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.

The RELATIVITY-098 trial showed no RFS improvement with nivolumab plus relatlimab versus nivolumab alone in resected stage III-IV melanoma. The trial was terminated as it failed to meet its primary ...

Merck and Daiichi Sankyo acknowledged a "voluntary pause" in the phase III program for the investigational antibody-drug conjugate ifinatamab deruxtecan following a higher-than-expected number of ...

Discover why Pfizer (PFE) remains a compelling income opportunity with a 7% yield, robust cash flow, and long-term growth ...

High levels of IB6 are often found in NSCLC, making it a good target for treatment. A preclinical study found that in lung cancer, IB6 was correlated with interleukin-8 levels and promoted cancer cell ...

NASA opens the International Space Station for scientists and researchers, inviting them to use the benefits of microgravity for private industry research, technology demonstrations, and more. Today, ...

European Space Agency (ESA) astronaut Thomas Pesquet removes the Protein Crystallization Facility hardware from an incubator ...

As previously reported, Wedbush downgraded Werewolf Therapeutics (HOWL) to Neutral from Outperform with a price target of $1, down from $3. The ...

NeOnc Technologies Holdings, Inc. ($NTHI) announced an update on their ongoing clinical study. Study Overview: NeOnc Technologies Holdings, Inc.

New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in ...